zunveyl
-
Alzheimer’s & Dementia Care
Zunveyl (benzgalantamine) Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Study
Top-line data from the BEACON study, a real-world observational study, indicate that Zunveyl (benzgalantamine) was associated with provider-reported improvements across…
Read More » -
Alzheimer’s & Dementia Care
Real-World BEACON Study Highlights Zunveyl’s Positive Impact on Alzheimer’s Patients in Long-Term Care, Paving Way for Further Research
Top-line data from the BEACON study, a significant real-world investigation, suggest that Zunveyl (benzgalantamine) was associated with notable improvements across…
Read More » -
Alzheimer’s & Dementia Care
Real-World BEACON Study Highlights Zunveyl’s Potential in Long-Term Alzheimer’s Care with Provider-Reported Improvements.
Top-line data emerging from the BEACON study, a real-world investigation into the therapeutic performance of Zunveyl (benzgalantamine), indicate a positive…
Read More » -
Alzheimer’s & Dementia Care
Zunveyl Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Long-Term Care Study
Top-line data from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was associated with significant provider-reported improvements…
Read More » -
Alzheimer’s & Dementia Care
Zunveyl Demonstrates Positive Provider-Reported Outcomes in Real-World Alzheimer’s Study Among Long-Term Care Patients
Provider observations with Zunveyl cannot prove cause and effect. Top-line data emerging from the BEACON study, a real-world investigation into…
Read More » -
Alzheimer’s & Dementia Care
Real-World Study Illuminates Zunveyl’s Impact on Cognition, Behavior, and Functioning in Long-Term Alzheimer’s Care.
Top-line data from the BEACON real-world study indicate that Zunveyl (benzgalantamine) was associated with significant provider-reported improvements across several critical…
Read More »
